Taxotere docetaxel: Phase III data

In the European, open-label Phase III TAX 323 trial, induction treatment with Taxotere docetaxel, cisplatin and fluorouracil produced median PFS of 11 months vs. 8.2 months for cisplatin and fluoroura...